Patents by Inventor Katarzyna CHMIELARSKA MASOUMI

Katarzyna CHMIELARSKA MASOUMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marker for Neural Stem Cells
    Publication number: 20250020646
    Abstract: The present application concerns methods for detecting and isolating a population of neural stem cells (NSC) or neural progenitor cells (NPC) based on expression of the marker integrin alpha10beta1; as well as use of said population of NSC or NPC for therapy, diagnosis and prognosis of disease and damage of the CNS.
    Type: Application
    Filed: October 2, 2024
    Publication date: January 16, 2025
    Applicant: Xintela AB
    Inventors: Evy Lundgren Åkerlund, Katarzyna Chmielarska Masoumi
  • Quality Assurance of Chondrocytes
    Publication number: 20230348857
    Abstract: The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.
    Type: Application
    Filed: June 21, 2023
    Publication date: November 2, 2023
    Applicant: Xintela AB
    Inventors: Evy Lundgren Åkerlund, Katarzyna Chmielarska Masoumi
  • Quality assurance of chondrocytes
    Patent number: 11725188
    Abstract: The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: August 15, 2023
    Assignee: Xintela AB
    Inventors: Evy Lundgren Åkerlund, Katarzyna Chmielarska Masoumi
  • INTEGRIN ALPHA10 AND AGGRESSIVE CANCER FORMS
    Publication number: 20220177591
    Abstract: The present invention relates to a composition for treatment of aggressive cancer forms including aggressive breast cancer, aggressive lung cancer, aggressive prostate cancer and aggressive pancreatic cancer, as well as metastatic cancer, comprising an antibody specifically binding to an integrin alpha10 polypeptide, or a fragment thereof. The present invention also relates to methods for diagnosis and treatment of said aggressive cancer forms. The present invention also relates to methods for predicting survival rate of individuals affected by said aggressive cancer forms.
    Type: Application
    Filed: April 15, 2020
    Publication date: June 9, 2022
    Applicant: Targinta AB
    Inventors: Evy Lundgren Åkerlund, Katarzyna Chmielarska Masoumi, Xiaoli Huang, Matilda Thorén
  • QUALITY ASSURANCE OF CHONDROCYTES
    Publication number: 20200377858
    Abstract: The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 3, 2020
    Applicant: Xintela AB
    Inventors: Evy Lundgren Åkerlund, Katarzyna Chmielarska Masoumi
  • Quality assurance of chondrocytes
    Patent number: 10781424
    Abstract: The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 22, 2020
    Assignee: Xintela AB
    Inventors: Evy Lundgren Åkerlund, Katarzyna Chmielarska Masoumi
  • Marker for Neural Stem Cells
    Publication number: 20190369093
    Abstract: The present application concerns methods for detecting and isolating a population of neural stem cells (NSC) or neural progenitor cells (NPC) based on expression of the marker integrin alpha10beta1; as well as use of said population of NSC or NPC for therapy, diagnosis and prognosis of disease and damage of the CNS.
    Type: Application
    Filed: August 17, 2017
    Publication date: December 5, 2019
    Applicant: Xintela AB
    Inventors: Evy LUNDGREN ÅKERLUND, Katarzyna CHMIELARSKA MASOUMI